Remarkably, MaR1 conferred protection against chemotherapy-induced peripheral neuropathy (CIPN) by inducing GPR37L1-dependent upregulation of surface KCNJ10 expression and KCNJ10-mediated K+ currents in SGCs. This evidence concerns the gene GPR37L1 and peripheral neuropathy.